CEP 37251

Drug Profile

CEP 37251

Alternative Names: ART 010; CEP-37251; EGX-010; OPG analogue; OPG variant; OPG variant protein; Osteoprotegerin analogue; Osteoprotegerin variant; Osteoprotegerin variant protein; OVP - Arana Therapeutics

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EvoGenix
  • Developer Teva Pharmaceutical Industries
  • Class Antineoplastics; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bone cancer
  • Discontinued Osteoporosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bone-cancer in USA (Parenteral)
  • 08 Jul 2010 Phase-I clinical trials in Osteoporosis in Australia (Parenteral)
  • 16 Feb 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top